S-1/A: Breeze Acquisition Corp. II Launches $125M IPO

Breeze Acquisition Corp. II, a blank check company, is launching a $125 million initial public offering to seek a business combination in high-growth technology and healthcare sectors.

Summary

• Breeze Acquisition Corp. II (Breeze II) is a newly formed Cayman Islands exempted company, operating as a Special Purpose Acquisition Company (SPAC).
• The company's primary objective is to effect a business combination (merger, acquisition, etc.) with one or more businesses within 24 months of the offering's closing.
• Breeze II intends to focus its search on companies with global operations and differentiated technology or capabilities, particularly in healthcare, biotechnology, advanced manufacturing, robotics, and artificial intelligence.
• The initial public offering consists of 12,500,000 units at $10.00 per unit, aiming to raise $125,000,000.
• Each unit comprises one ordinary share and one right, with each right entitling the holder to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.
• Underwriters have a 45-day option to purchase up to an additional 1,875,000 units to cover over-allotments.
• Breeze Sponsor II, LLC, the sponsor, will purchase 447,500 private placement units (or up to 475,625 if the over-allotment option is exercised in full) at $10.00 per unit, for an aggregate of $4,475,000 (or $4,756,250).
• A total of $125,000,000 (or $143,750,000 with full over-allotment) from the offering and private placement will be deposited into a U.S.-based trust account.
• As of December 31, 2025, the company reported a net tangible book deficit of $(278,829) and a net loss of $(126,339) since its inception on August 20, 2025.
• Public shareholders are expected to incur an immediate and substantial dilution of approximately 96.7% (or $9.67 per share) upon the closing of the offering, primarily due to the nominal price paid by the sponsor for founder shares ($0.005 per share).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk offering due to the 'going concern' warning, significant immediate dilution for public shareholders, and inherent uncertainties of a blank check company, despite the management's prior SPAC experience.

Positives

• The management team has a proven track record, having successfully sponsored and completed the full SPAC lifecycle with Breeze I, culminating in the public listing of YD Bio Limited on Nasdaq.
• The board of directors has been strengthened with new independent directors, bringing deeper international, financial, governance, and operational expertise.
• The company has a clear strategic focus on high-growth sectors such as healthcare, biotechnology, advanced manufacturing, robotics, and artificial intelligence, which are attractive to investors.
• The team emphasizes institutional-grade diligence, legal, financial, and compliance practices throughout the transaction process.
• Sponsor capital is at risk, and the compensation structure is designed to reward long-term value creation, indicating alignment of interests.
• The SPAC structure offers a potentially more expeditious and cost-effective path for target businesses to become publicly listed compared to traditional IPOs.

Negatives

• Public shareholders will experience an immediate and substantial dilution of approximately 96.7% (or $9.67 per share) upon the closing of the offering, primarily due to the sponsor acquiring founder shares at a nominal price of $0.005 per share.
• The independent registered public accounting firm's report contains an explanatory paragraph expressing "substantial doubt about our ability to continue as a going concern" as of December 31, 2025, due to no cash and a working capital deficit.
• Potential for further significant dilution exists if the company raises additional funds through equity or convertible debt issuances, or if working capital loans from the sponsor are converted into private placement units.
• Conflicts of interest may arise as officers and directors have other fiduciary or contractual obligations and a financial incentive to complete a business combination to avoid their founder shares expiring worthless.
• The company is a blank check company with no operating history or revenues, making it a highly speculative investment.
• Public shareholders may not have the opportunity to vote on the initial business combination, and even if a vote is held, the initial shareholders' voting agreements increase the likelihood of approval.
• The company is exempt from certain investor protections normally afforded to blank check offerings under Rule 419 of the Securities Act.

Risks

• Public shareholders may not be afforded an opportunity to vote on the proposed initial business combination, and even if a vote is held, initial shareholders' votes increase the likelihood of approval.
• The only opportunity for public shareholders to effect their investment decision regarding a potential business combination may be limited to exercising their right to redeem shares for cash.
• The ability of public shareholders to redeem their shares for cash may make the company's financial condition unattractive to potential business combination targets, making it difficult to secure a deal.
• Large redemptions by public shareholders could prevent the completion of the most desirable business combination or significantly dilute remaining investments.
• The sponsor, initial shareholders, directors, officers, advisors, or their affiliates may purchase public shares or Share Rights, which could influence a vote on a proposed business combination and reduce the public float.
• Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.
• Changes in laws or regulations, including the new SEC SPAC Rules, or a failure to comply, may adversely affect the company's business and ability to complete an initial business combination.
• The company may be deemed an investment company under the Investment Company Act, which could impose burdensome compliance requirements and restrict activities.
• Certain agreements related to the offering may be amended or their provisions waived without shareholder approval, potentially benefiting the sponsor, officers, and directors.
• The share price of the combined company may decline after the initial business combination below the initial value of the units sold in this offering.
• Changes in international trade policies, tariffs, and treaties may materially adversely affect the search for a target or the performance of a post-combination company.
• Public shareholders will not have any rights or interests in funds from the trust account, except under certain limited redemption circumstances; Share Rights will expire worthless if no business combination is completed.
• Nasdaq may delist the company's securities, limiting investors' ability to trade and subjecting the company to additional restrictions.
• The nominal purchase price paid by the sponsor for founder shares results in significant dilution to the implied value of public shares upon business combination.
• The value of founder shares is likely to be substantially higher than the nominal price paid, even if the trading price of ordinary shares declines post-business combination.
• An investment in this offering may result in uncertain U.S. federal income tax consequences, including potential challenges by the IRS on purchase price allocation.
• The company is a blank check company with no operating history and no revenues, providing no basis to evaluate its ability to achieve its business objective.
• The company may be classified as a Passive Foreign Investment Company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. investors.
• A U.S. federal excise tax could be imposed on redemptions if the initial business combination involves a U.S. company and the company domesticates.
• The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern.
• Past performance by the management team is not a guarantee of future success or ability to identify a suitable business combination candidate.
• Cyber incidents or attacks directed at the company could result in information theft, data corruption, operational disruption, and/or financial loss.
• The company may be unable to obtain additional financing to complete its initial business combination or to fund the operations and growth of a target business.
• The company may only be able to complete one business combination, leading to a lack of diversification and dependence on a single business.
• Competition for business combination opportunities may increase costs or result in the inability to find or consummate a suitable target.
• Adverse developments affecting the financial services industry could adversely affect the company's business, financial condition, or prospects.
• The requirement to furnish target business financial statements may limit the pool of potential targets.
• Compliance obligations under the Sarbanes-Oxley Act may make it more difficult and expensive to effectuate an initial business combination.
• Management of a prospective target business may be unfamiliar with United States securities laws, leading to regulatory issues post-business combination.
• Exchange rate fluctuations and currency policies may diminish a target business's ability to succeed in international markets.
• If the company effects a business combination with a foreign company, its operations and prospects will be subject to the economic, political, and legal policies of that country.
• The company is dependent upon its officers and directors, and their loss or reduced time commitment could adversely affect its ability to operate.
• Key personnel may negotiate employment or consulting agreements with a target business, potentially creating conflicts of interest.
• Officers and directors will allocate their time to other businesses, causing conflicts of interest in their determination of time devoted to the company's affairs.
• Officers, directors, security holders, and their respective affiliates may have competitive pecuniary interests that conflict with the company's interests.
• Members of the management team and board of directors may be involved in civil disputes or governmental investigations unrelated to the company's business, which could negatively affect its reputation and ability to complete a business combination.

Future Outlook

The company intends to identify and acquire a business with an enterprise value between $400 million and $1 billion within 24 months of the offering's closing. The strategic focus is on companies with global operations and differentiated technology or capabilities in healthcare, biotechnology, advanced manufacturing, robotics, and artificial intelligence. The company may seek additional capital through PIPE transactions, at-the-market facilities, forward purchase agreements, or bridge financing to facilitate a business combination. The company expects to incur increased expenses as a public company and will generate non-operating income from interest on the trust account.

Management Comments

• "Breeze Acquisition Corp. II builds on the success of Breeze I, which announced and consummated a merger with YD Biopharma Limited, a Taiwan-based life sciences company, ultimately listing YD Bio Limited on Nasdaq."
• "Our team is focused on value creation through a combination of operational insight, capital market expertise, and a rigorous diligence and transaction process."
• "We intend to identify companies with attractive business fundamentals, capable leadership teams, and compelling growth trajectories that are well positioned to benefit from becoming a publicly listed company."
• "We believe our demonstrated ability to source and structure capital on numerous transactions gives us a strategic advantage in ensuring the completion and success of our business combination."
• "We believe Breeze II represents a sophisticated and value-aligned partner for companies seeking growth capital, public market access, and experienced stewardship through the de-SPAC process."

Industry Context

StockSavvy.ai notes that Breeze Acquisition Corp. II is entering a competitive SPAC market, aiming to leverage its management's prior success with Breeze I (YD Biopharma Limited listing on Nasdaq). The strategic focus on high-growth sectors like healthcare, biotech, advanced manufacturing, robotics, and AI aligns with current investor interest in innovation and technology. However, the broader SPAC market has seen increased liquidations from 2022-2025, indicating a more challenging environment for identifying and completing business combinations, which could impact Breeze II's ability to find a suitable target and achieve its objectives. The new SEC SPAC Rules, effective July 1, 2024, also introduce additional disclosure requirements and potential regulatory scrutiny, increasing costs and complexity for SPACs like Breeze II.

Comparison to Industry Standards

• The SPAC structure, offering units of one ordinary share and one-tenth of a right, is a common model, with the 1/10th right being less dilutive than full warrants often seen in older SPAC structures, which is a slight improvement for public shareholders compared to some historical SPACs.
• The management team's prior success with Breeze I and the listing of YD Bio Limited on Nasdaq provides a tangible track record, which is a positive differentiator in an industry where many SPACs are led by teams without prior de-SPAC experience.
• The stated 96.7% immediate dilution to public shareholders due to founder shares purchased at a nominal price ($0.005 per share vs. $10.00 IPO price) is a significant concern and is a common criticism of the SPAC model, often exceeding dilution seen in traditional IPOs.
• The commitment to place 100% of public offering proceeds into a trust account, invested in U.S. government treasury obligations or money market funds, is standard practice for SPACs to protect public shareholder capital.
• The 24-month completion window is a typical timeframe for SPACs to identify and consummate a business combination.
• The target enterprise value range of $400 million to $1 billion is consistent with many SPACs seeking mid-to-large cap private companies.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding is currently pending against the company or any members of its management team in their capacities as such.

Related Party Transactions

• Breeze Sponsor II, LLC (Sponsor) purchased 5,050,676 founder shares for an aggregate price of $25,000 (approximately $0.005 per share).
• The Sponsor has committed to purchase 447,500 private placement units (or up to 475,625 if the over-allotment option is exercised in full) at $10.00 per unit, for an aggregate purchase price of $4,475,000 (or $4,756,250).
• The company will pay the Sponsor $5,000 per month for office space, utilities, and secretarial and administrative support.
• Up to $300,000 in loans made by the Sponsor to cover offering-related and organizational expenses will be repaid upon the closing of the offering.
• The Sponsor, officers, and directors, or their affiliates, may provide up to $1,500,000 in working capital loans, which may be convertible into private placement units at $10.00 per unit at the lender's option.
• The Sponsor, officers, and directors have agreed to waive their redemption rights with respect to their founder shares and private placement shares, and their rights to liquidating distributions from the trust account if the company fails to complete an initial business combination.
• The company may pay finders fees, advisory fees, consulting fees, or success fees to the Sponsor, officers, or directors, or their respective affiliates, for services rendered in connection with a business combination, paid from funds held outside the trust account.
• The company will obtain an opinion from an independent investment banking firm or another independent entity regarding the fairness of any business combination with an affiliated entity from a financial point of view to public shareholders.

Stakeholder Impact

• **Shareholders (Public)**: Face significant immediate dilution (96.7%) due to the sponsor's low-cost founder shares. Their investment in the trust account is protected for redemption in certain scenarios, but Share Rights will expire worthless if no business combination occurs. Voting influence may be limited by the sponsor's ownership block.
• **Shareholders (Sponsor/Insiders)**: Benefit from the low-cost acquisition of founder shares, creating a strong incentive to complete a business combination. Their investment is at risk if a business combination is not completed within the timeframe, but they stand to make substantial profits even if the post-combination share price declines significantly from the IPO price.
• **Employees (future target company)**: A successful business combination could provide the target company with enhanced access to capital and a public market profile, potentially benefiting its employees through growth opportunities and incentives.
• **Customers/Suppliers (future target company)**: The target company's customers and suppliers could benefit from the increased capital and public visibility that a business combination with Breeze II might provide, potentially leading to expanded operations and improved services.
• **Creditors**: The trust account is designed to protect public shareholders' capital. However, if third-party claims are successfully made against the company and waivers are not enforceable, or if the sponsor cannot satisfy its indemnification obligations, the funds available for public shareholder redemptions could be reduced below the initial $10.00 per share.

Next Steps

• Complete the initial public offering of 12,500,000 units at $10.00 per unit.
• Deposit $125,000,000 of proceeds into a U.S.-based trust account.
• Apply to list units on The Nasdaq Global Market under the symbol BREZU.
• File a Current Report on Form 8-K with an audited balance sheet reflecting gross proceeds.
• Issue a press release announcing when separate trading of ordinary shares (BREZ) and Share Rights (BREZR) will begin (expected on the 52nd day post-prospectus date, unless earlier allowed by IB Capital LLC).
• Identify and consummate an initial business combination within 24 months of the offering's closing, focusing on companies with global operations and differentiated technology in healthcare, biotechnology, advanced manufacturing, robotics, and AI.
• Establish and maintain an audit committee, compensation committee, and nominating and corporate governance committee.
• Comply with Sarbanes-Oxley Act internal control requirements for the fiscal year ending December 31, 2026.

Key Dates

Recommendation

StockSavvy.ai recommends a "hold" for potential investors. While the management team has a proven track record with a prior SPAC, the significant immediate dilution for public shareholders (96.7%) and the "going concern" warning from the auditor present substantial risks. The speculative nature of a blank check company, coupled with potential conflicts of interest and a challenging SPAC market, suggests that while there is potential for a successful business combination, the current offering carries a high degree of uncertainty and risk for new investors. A "hold" reflects caution due to these risks, advising investors to await further clarity on a target business and the company's financial stability post-IPO.

Keywords

SPAC, Initial Public Offering, Blank Check Company, Business Combination, Merger, Acquisition, Healthcare Technology, Biotechnology, Advanced Manufacturing, Robotics, Artificial Intelligence, SEC Filing, S-1/A, Cayman Islands, Nasdaq Listing, Dilution, Trust Account, Founder Shares, Private Placement Units, Redemption Rights, Corporate Governance, Risk Factors, J. Douglas Ramsey, Breeze Acquisition Corp. II